We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

TNXP Tonix Pharmaceuticals Holding Corporation

0.0702 (6.44%)
Last Updated: 10:03:33
Delayed by 15 minutes


Draw Mode:

Volume 4,916,499
Bid Price 1.16
Ask Price 1.17
News -
Day High 1.24


52 Week Range


Day Low 1.11
Share Name Share Symbol Market Stock Type
Tonix Pharmaceuticals Holding Corporation TNXP NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.0702 6.44% 1.1602 10:03:33
Open Price Low Price High Price Close Price Previous Close
1.15 1.11 1.24 1.09
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
24,598 4,916,499 US$ 1.17 US$ 5,761,871 - 1.08 - 63.68
Last Trade Type Quantity Price Currency
10:03:33 100 US$ 1.1602 USD

Tonix Pharmaceuticals Holding Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
67.99M 58.61M - 7.77M -116.66M -1.99 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Tonix Pharmaceuticals News

Date Time Source News Article
6/13/202416:24Edgar (US Regulatory)Form 8-K - Current report
6/13/202416:00GlobeNewswire Inc.Tonix Pharmaceuticals Announces Closing of $4.0 Million..
6/12/202416:01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]
6/12/202408:00GlobeNewswire Inc.Tonix Pharmaceuticals Announces Pricing of $4.0 Million..
6/11/202416:17GlobeNewswire Inc.Tonix Pharmaceuticals Announces Proposed Public Offering
6/11/202415:49Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]
6/10/202407:53Edgar (US Regulatory)Form 8-K - Current report
6/06/202410:21Edgar (US Regulatory)Form 8-K - Current report
6/06/202410:00GlobeNewswire Inc.Tonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split
6/06/202407:05Edgar (US Regulatory)Form 8-K - Current report
6/06/202407:00GlobeNewswire Inc.Tonix Pharmaceuticals Announces Two Oral Presentations and..
6/05/202407:00GlobeNewswire Inc.Tonix Pharmaceuticals Announces Poster Presentation at the..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No TNXP Message Board. Create One! See More Posts on TNXP Message Board See More Message Board Posts

Historical TNXP Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week3.3283.6321.082.313,408,115-2.17-65.14%
1 Month6.25286.721.084.303,653,532-5.09-81.45%
3 Months11.3611.46011.085.403,259,166-10.20-89.79%
6 Months13.475222.13761.087.952,454,643-12.32-91.39%
1 Year56.9663.681.0810.871,459,764-55.80-97.96%
3 Years266.00958.001.08123.158,067,171-264.84-99.56%
5 Years3,300.003,580.001.08176.789,838,712-3,298.84-99.96%

Tonix Pharmaceuticals Description

Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio is composed of immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. Tonix's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500 which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Tonix's rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome.

Your Recent History

Delayed Upgrade Clock